Skip to Content

Hormonal and Reproductive Epidemiology Branch Distinguished Lecture Series

The Hormonal and Reproductive Epidemiology Branch (HREB) launched the Distinguished Lecture Series in 2004. Each year, a prominent scientist is invited to visit for two days to give a lecture and meet with DCEG staff to discuss issues relevant to research on causes of hormonal and reproductive cancers. The objectives of this series are to expand and intensify contacts between intramural and extramural investigators, provide an opportunity for junior staff to meet with distinguished scientists, and stimulate new opportunities for research in the area of hormonal and reproductive cancers.

Previous HREB Distinguished Lectures

October, 2011
Dr. Malcolm Pike, Attending Epidemiologist at Memorial Sloan-Kettering's Epidemiology Service in New York.

Malcom Pike, profile photoDr. Pike holds a Ph.D in Mathematical Statistics from Aberdeen University in Scotland. Before he joined Memorial Sloan-Kettering, he was University Professor of Preventive Medicine at the USC/Norris Comprehensive Cancer Center. Dr. Pike's research interests are in the etiology and chemoprevention of breast, endometrial and ovarian cancer. His contributions to the understanding of hormone-related breast cancer have made him a renowned researcher in the field of epidemiology. He holds many honors which include membership in the Institute of Medicine as well as the 2008 Distinguished Achievement Award from the American Society of Preventive Oncology.

December, 2009
Dr. Jack Cuzick, head of the Center for Epidemiology, Mathematics and Statistics at Cancer Research UK in London and John Snow Professor of Epidemiology at Wolfson Institute of Preventive Medicine at Queen Mary, University of London.

Dr.Cuzick's presentation was titled “The prevention of breast cancer: progress and obstacles”. He holds a Ph.D. in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and is also involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behavior of early prostate cancer. (Biography modified from Cancer Research UK)

November, 2008
Dr. Norman F. Boyd, Senior Scientist at the Campbell Family Institute for Breast Cancer Research at the Ontario Cancer Institute and Professor of Medicine at the University of Toronto

Dr. Boyd’s pioneering work in developing improved methods to identify components of breast tissue at increased risk of cancer, understanding the relationship between these components and other risk factors, and exploiting this information in the prevention of breast cancer has earned him international recognition. During his visit, Dr. Boyd presented a seminar titled, “Breast tissue composition and susceptibility to breast cancer.” He discussed potential mechanisms of breast cancer risk associated with mammographic density, a strong and independent risk factor for breast cancer.

September, 2007
Dr. Lynn C. Hartman, the Blanche R. and Richard J. Erlanger Professor of Medical Research, Professor of Oncology Mayo Clinic College of Medicine

Dr. Hartman's work has focused on predictors of risk for breast and ovarian cancers, evaluation of novel therapeutics for ovarian cancer, and prevention strategies for breast and gynecologic cancers.  Dr. Hartman is a member of professional societies including the American Association for Cancer Research (AACR), the American Association for the Advancement of Science (AAAS), the Society of Gynecologic Oncology (SGO), and Women in Cancer Research (WICR).  Her presentation was entitled Risk Prediction Strategies for Breast Cancer.

January, 2005
Dr. Rudolf Kaaks of the International Agency for Research on Cancer (IARC)

Dr. Kaaks, former head of the Hormones and Cancer research team at International Agency for Research on Cancer and currently at the Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, is a leading expert on steroid hormones and cancer and a co-PI on the European Prospective Investigation Into Cancer and Nutrition Cohort (EPIC) gave an insightful presentation on "Overweight, physical inactivity, and cancer risk: Hormonal mechanisms."  During his visit, he also emphasized the importance of investigating energy balance, exogenous hormones, and genetic susceptibility in future studies to clarify the underlying mechanisms linking obesity to higher cancer risk.

June, 2004
Dr. Frank Stanczyk, Professor of Preventive Medicine at the University of Southern California

Dr. Stanczyk is an internationally recognized authority on the metabolism, pharmacokinetics, and measurement of steroid hormones, and he has collaborated extensively on epidemiologic studies with scientists at several cancer centers and universities as well as those at NCI. During his visit, he challenged epidemiologists to consider measuring complete androgen/estrogen profiles and relevant metabolites in serum and tissue particularly using gas chromatography or liquid chromatography-mass spectrometry, tools for peering into the structure of molecules by separating them based on size and charge. He gave a provocative seminar entitled "Measurements of steroid hormones in epidemiologic studies of breast and prostate cancers: What is missing?"